Novo Nordisk A/S

NVO

Equity

ISIN null / Valor 461641

New York Stock Exchange, Inc (2026-02-20)

USD 47.42-2.13%

Novo Nordisk A/S
UMushroom community rating:

4.06 19 votes No rating yet

NegativeNeutralPositive

About company

Novo Nordisk A/S is a Danish multinational pharmaceutical company focused principally on diabetes care and related metabolic disorders, developing, manufacturing and commercializing medicines and delivery devices—most prominently insulin and GLP‑1 receptor agonists used in type 2 diabetes and obesity treatment—and it also markets therapies for haemophilia, growth disorders and hormone replacement. The company combines clinical research and development with large‑scale manufacturing and worldwide commercial operations and is publicly listed on the Copenhagen stock exchange. Internally, Novo Nordisk operates under corporate conduct frameworks (OneCode and the Novo Nordisk Way) that define expected standards of behaviour and decision‑making for employees.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-43.4%1Y

-33.0%3Y

28.0%5Y

Performance

54.5%1Y

42.2%3Y

37.4%5Y

Volatility

159764 M

Market cap (USD)

12,285,848

Daily traded volume (Shares)

86.86 / 85.69

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.06

19 votes

Performance:

3.74

Innovation:

4.39

Society:

4.09

Nature:

4.00

Daniela Isabel Fernandez

Spain, 10 Jan 2026

Inversion a largo plazo

Hubert Joo

Spain, 06 Jan 2026

Novo Nordisk combines strong innovation leadership in diabetes and obesity treatments with solid cash generation and improving dividend prospects. While recent volatility reflects valuation adjustments, its long-term growth drivers and societal impact remain structurally attractive.